Goldman Sachs Sees US Stock Buybacks Outpacing Equity Issuance as AI Funding Rises 
UOB Q2 Net Profit Rises 10% as Wealth Management Growth Boosts Earnings 
Cloudflare Stock Jumps 15% as Earnings Beat Estimates, 2026 Outlook Raised 
Sony, TSMC Eye $6.3 Billion Japan Chip Venture for Next-Gen Image Sensors 
Treasury Wine Estates Shares Jump as U.S. Overhaul Lifts FY2026 Outlook 
Moderna Wins FDA Approval for mFLUSIVA mRNA Flu Vaccine for Adults 50+ 
SanDisk Q4 Earnings Beat Estimates as Q1 Revenue Outlook Meets Expectations 
ADNOC Gas Targets Up to $4B Profit in 2026 
Shein Scales Back Vietnam Operations as US Trade Rules Shift 
Sinopec Boosts Russian ESPO Oil Purchases as Middle East Supply Tightens 
Deutsche Bank Upgrades Persimmon to Buy After Strong First-Half Results 
Airbnb Stock Jumps After Q2 Earnings Beat, Strong 2026 Outlook 
OpenAI Restricts Astra AI Over Cyberattack Risks 
AMP Shares Surge 13% After Strong Profit and A$150 Million Buyback 
Alibaba Plans Revenue-Sharing Model for Qwen3.8-Max AI Commercial Users 
Daimler Truck Q2 Profit Falls 18%, 2026 Outlook Raised 
Western Digital Q4 Earnings Beat Estimates as FY2027 Outlook Tops Expectations 
DURHAM, N.C., Feb. 22, 2018 -- Chimerix, Inc. (Nasdaq:CMRX), a biopharmaceutical company developing novel antivirals for the growing population of immunocompromised patients, today announced that it will host a live conference call and audio webcast on Thursday, March 1, 2018 at 8:30 a.m. ET to report financial results for the fourth quarter and full year ended December 31, 2017, and to provide a business overview.
To access the live conference call, please dial (877) 354-4056 (domestic) or (678) 809-1043 (international) at least five minutes prior to the start time, and refer to conference ID 1153769. A live audio webcast of the call will also be available on the Investors’ section of the Company's website, www.chimerix.com. An archived webcast will be available on the Chimerix website approximately two hours after the event.
About Chimerix
Chimerix is a biopharmaceutical company dedicated to discovering, developing and commercializing medicines that improve outcomes for immunocompromised patients. Chimerix's proprietary lipid conjugate technology and Compound Library have produced brincidofovir (BCV, CMX001); CMX157, which was licensed to ContraVir Pharmaceuticals; and a new clinical candidate, CMX521, the first direct-acting antiviral specifically for the treatment and prevention of norovirus to enter clinical testing. For further information, please visit Chimerix's website, www.chimerix.com.
CONTACT:
Investor Relations:
Michelle LaSpaluto
919-972-7115
[email protected]
or
Will O’Connor
Stern Investor Relations
[email protected]
212-362-1200
Media:
Becky Vonsiatsky
W2O Group
[email protected]
413-478-2003
